Trial Profile
CLINICAL STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (NIVOLUMABIPILIMUMAB AT 1MG/KG – NIVOIPI01)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2018 New trial record